New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control
Completed
This study tested a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to find the safest dose and see if the treatment could shrink tumors. The study was completed, but results …
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 26, 2026 20:03 UTC